Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Alkermes plc (ALKS)

« Back to company index

ALKS Chatter Timeline

Stock Ticker for ALKS

Most Active Tweeters for ALKS

UserTweets
@sleekoptions 4
@ConsumerFeed 4
@gcassidy718 3
@AmericanBanking 3
@TickerReport 2

Recent Tweets for ALKS

1stOncology @1stOncology
#Alkermes Announces New Data From #ALKS4230 Clinical Development Program at #SITC19 $ALKS https://t.co/ghZEk8bLUK
November 10th 2019, 10:11am
TickerReport @TickerReport
Michael J. Landine Sells 20,000 Shares of Alkermes Plc $ALKS Stock https://t.co/veSOwB8LMl
November 10th 2019, 8:11am
dailypoliticaln @dailypoliticaln
Alkermes Plc $ALKS SVP Sells $395,200.00 in Stock https://t.co/1IoAEUpCFp
November 10th 2019, 8:11am
TranscriptDaily @TranscriptDaily
Alkermes Plc $ALKS CEO Sells $1,382,638.95 in Stock https://t.co/eBieI4xtfK
November 10th 2019, 6:11am
stocknewstimes @stocknewstimes
Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/gd5QJFjY3t
November 10th 2019, 6:11am
Gambiste1 @Gambiste1
RT @gcassidy718: $ALKS I’ll probably buy on the dip. Still need to do more research. 2.08 % https://t.co/hUvnS3GBI1
November 10th 2019, 12:11am
gcassidy718 @gcassidy718
$ALKS I’ll probably buy on the dip. Still need to do more research. 2.08 % https://t.co/hUvnS3GBI1
November 9th 2019, 10:11pm
bbnsnews @bbnsnews
Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/6ptQchNKZ0
November 9th 2019, 8:11am
ConsumerFeed @ConsumerFeed
Alkermes SVP Michael Landine Sells $395,200.00 in $ALKS https://t.co/AXqeQXv2LP
November 9th 2019, 3:11am
ConsumerFeed @ConsumerFeed
Alkermes CEO Richard Pops Sells $1,382,638.95 in $ALKS https://t.co/678IieyQeW
November 9th 2019, 3:11am
AmericanBanking @AmericanBanking
Michael J. Landine Sells 20,000 Shares of Alkermes Plc $ALKS Stock https://t.co/8RoAdYkKXP #stocks
November 8th 2019, 7:11pm
bs2537 @bs2537
$ALKS at #SITC2019 https://t.co/syuKWC44Pi
November 8th 2019, 7:11pm
AmericanBanking @AmericanBanking
Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/j3fVL4CPSC #stocks
November 8th 2019, 7:11pm
TickerReport @TickerReport
Alkermes Plc $ALKS CEO Richard F. Pops Sells 69,795 Shares https://t.co/RaGjfOLvi9
November 8th 2019, 7:11pm
WatchlistN @WatchlistN
Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/AsGMfgLu2b
November 8th 2019, 6:11pm
gcassidy718 @gcassidy718
$ALKS Looking for any entry here......... ;) 2.06 % change recently https://t.co/hUvnS3GBI1
November 8th 2019, 5:11pm
MonitorAction @MonitorAction
$ALKS Michael Landine Dumps 20K Shares of Alkermes plc. https://t.co/nADxRH1XfW
November 8th 2019, 4:11pm
InsiderAlertsIA @InsiderAlertsIA
$ALKS: New Insider Filing on Director and CEO, Alkermes plc RICHARD F POPS: https://t.co/Sbepyy4c7e
November 8th 2019, 4:11pm
sleekoptions @sleekoptions
Peak profit for the last 6 expired option alerts for $ALKS -14.29 % | -2.86 % | -1.60 % | 165.71 % | -10.26 % | -3.… https://t.co/GvEalPT2yP
November 8th 2019, 2:11pm
sleekoptions @sleekoptions
$ALKS - View historical options performance for ALKS https://t.co/8OWl95LwVV https://t.co/KP8qCkOSuP
November 8th 2019, 2:11pm
sleekoptions @sleekoptions
$ALKS - Last six months, 2 option alerts peaked above 100% after they were triggered by the algo… https://t.co/dxHARW6ZN1
November 8th 2019, 2:11pm
Briefingcom @Briefingcom
$ALKS: Alkermes presents new data from ARTISTRY clinical development program related to ALKS 4230 at the Society fo… https://t.co/WdJNBWWyRv
November 8th 2019, 9:11am
IncredibleTrade @IncredibleTrade
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunother... $ALKS… https://t.co/MSMEc1zTMg
November 8th 2019, 8:11am
EpiscopalianTra @EpiscopalianTra
$ALKS Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS… https://t.co/ICHNO0ZsXb
November 8th 2019, 8:11am
WallStCards @WallStCards
$ALKS: Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS… https://t.co/KnOjvVGelJ
November 8th 2019, 7:11am
newswelldone @newswelldone
$ALKS: Alkermes Announces New Data From ALKS 4230 Clinical …: https://t.co/UlxXoFA7xr
November 8th 2019, 7:11am
gcassidy718 @gcassidy718
$ALKS what a Company 2.64 % change recently https://t.co/hUvnS3GBI1
November 7th 2019, 5:11pm
EpiscopalianTra @EpiscopalianTra
Does anybody know how much this will worth to $ALKS? They do have upcoming data release and I want to know about th… https://t.co/dT1nbQUhrK
November 6th 2019, 2:11pm
1stOncology @1stOncology
#Alkermes to Present Data From #ALKS4230 Clinical Development Program at #SITC19 $ALKS https://t.co/pnM3ykb6Xv
November 5th 2019, 7:11am
TheMarketsDaily @TheMarketsDaily
Alkermes $ALKS Given New $26.00 Price Target at HC Wainwright https://t.co/qfwDGEHeHD
November 5th 2019, 3:11am
OlympiaReport @OlympiaReport
Alkermes $ALKS PT Lowered to $26.00 at HC Wainwright https://t.co/C6Wl5v5DgO
November 4th 2019, 5:11pm
dispatchtribune @dispatchtribune
Alkermes $ALKS PT Lowered to $26.00 at HC Wainwright https://t.co/jHVgpg2bTN
November 4th 2019, 5:11pm
WeekHerald @WeekHerald
Alkermes $ALKS Price Target Cut to $26.00 https://t.co/vBcKYoLBrY
November 4th 2019, 5:11pm
ThisLincolnian @ThisLincolnian
Alkermes $ALKS Price Target Cut to $26.00 https://t.co/Xlrj9tMkXn
November 4th 2019, 5:11pm
SwingTradeBot @SwingTradeBot
Recent $ALKS technical alerts: MACD Bullish Centerline Cross plus 5 more alerts... https://t.co/LZXCqc9JTR
November 4th 2019, 1:11pm
biostockinfo @biostockinfo
RT @TomSilver39: Leerink:" #SitC2019 SITC Planner Highlights: data from $ALKS is likely to shape expectations for other “not alpha” interle…
November 4th 2019, 10:11am
TomSilver39 @TomSilver39
Leerink:" #SitC2019 SITC Planner Highlights: data from $ALKS is likely to shape expectations for other “not alpha”… https://t.co/1Mc9eZeXXS
November 4th 2019, 10:11am
adamfeuerstein @adamfeuerstein
$HALO is like a smaller $ALKS — good at helping other companies improve the delivery/administration of their drugs,… https://t.co/LzQLbSBPXD
November 4th 2019, 7:11am
newswelldone @newswelldone
$ALKS: Alkermes to Present Data From ALKS 4230 Clinical Development …: https://t.co/9xF1z3HyhF
November 4th 2019, 7:11am
ProVesting @ProVesting
$ALKS $MRK: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC …: https://t.co/Llsuds4UL8
November 3rd 2019, 11:11am
DataTrials @DataTrials
$ALKS Phase 3 Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals…NCT03711318.… https://t.co/uaYleMYu6u
November 2nd 2019, 9:11am
AmericanBanking @AmericanBanking
Alkermes $ALKS Receives Neutral Rating from HC Wainwright https://t.co/DHcNOofrtr #stocks
November 1st 2019, 10:11pm
marketexclusive @marketexclusive
$ALKS Alkermes Plc (NASDAQ:ALKS) had its Neutral rating reiterated by HC Wainwright with a $26.00 price target… https://t.co/6qEWdtao4v
November 1st 2019, 10:11am
BlueBioNow @BlueBioNow
$ALKS Turn Green.. NOT Red... -3.01 % https://t.co/pOSy7CeMJf
October 31st 2019, 9:10pm
SwingTradeBot @SwingTradeBot
50 DMA Resistance today: $NBY $ALKS ... https://t.co/mnYaiRq1wk
October 31st 2019, 12:10pm
bs2537 @bs2537
Alkermes (NASDAQ: ALKS), Revisting Before Upcoming ALKS-4230 Immuno-Oncology Data $ALKS: https://t.co/IG8TBQz5Wu
October 31st 2019, 10:10am
ChartMill @ChartMill
$ALKS: The EPS has grown by an impressive 81.08% over the past year. https://t.co/gWBFt1TJWR https://t.co/ErJFKGfPsM
October 30th 2019, 4:10pm
BankTheTrade @BankTheTrade
$ALKS(20.02) up 2.20 (ALKS) said Wednesday that U.S. Food and Drug Administration approved Vumerity for the treat… https://t.co/RYy8nNYScp
October 30th 2019, 8:10am
Hall8Jack @Hall8Jack
RT @BioStocks: $BIIB and $ALKS Announce FDA Approval Of VUMERITY For Multiple Sclerosis
October 30th 2019, 8:10am
1MinuteStock @1MinuteStock
Not sure what to do with $ALKS? Explore our #fundamental pros and cons. https://t.co/T7pUyDYuUE
October 30th 2019, 8:10am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.